274 related articles for article (PubMed ID: 29203461)
1. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.
Liu H; Murphy CJ; Karreth FA; Emdal KB; White FM; Elemento O; Toker A; Wulf GM; Cantley LC
Cancer Discov; 2018 Mar; 8(3):354-369. PubMed ID: 29203461
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast.
Beca F; Lee SSK; Pareja F; Da Cruz Paula A; Selenica P; Ferrando L; Gularte-Mérida R; Wen HY; Zhang H; Guerini-Rocco E; Rakha EA; Weigelt B; Reis-Filho JS
Histopathology; 2019 Dec; 75(6):931-937. PubMed ID: 31361912
[TBL] [Abstract][Full Text] [Related]
3. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863
[No Abstract] [Full Text] [Related]
4. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations in sporadic triple negative breast cancer.
Pop LA; Cojocneanu-Petric RM; Pileczki V; Morar-Bolba G; Irimie A; Lazar V; Lombardo C; Paradiso A; Berindan-Neagoe I
Breast; 2018 Apr; 38():30-38. PubMed ID: 29202330
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
Kawazu M; Kojima S; Ueno T; Totoki Y; Nakamura H; Kunita A; Qu W; Yoshimura J; Soda M; Yasuda T; Hama N; Saito-Adachi M; Sato K; Kohsaka S; Sai E; Ikemura M; Yamamoto S; Ogawa T; Fukayama M; Tada K; Seto Y; Morishita S; Hazama S; Shibata T; Yamashita Y; Mano H
PLoS Genet; 2017 Jun; 13(6):e1006853. PubMed ID: 28636652
[TBL] [Abstract][Full Text] [Related]
7. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
[TBL] [Abstract][Full Text] [Related]
9. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
10. Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.
Matissek KJ; Onozato ML; Sun S; Zheng Z; Schultz A; Lee J; Patel K; Jerevall PL; Saladi SV; Macleay A; Tavallai M; Badovinac-Crnjevic T; Barrios C; Beşe N; Chan A; Chavarri-Guerra Y; Debiasi M; Demirdögen E; Egeli Ü; Gökgöz S; Gomez H; Liedke P; Tasdelen I; Tolunay S; Werutsky G; St Louis J; Horick N; Finkelstein DM; Le LP; Bardia A; Goss PE; Sgroi DC; Iafrate AJ; Ellisen LW
Cancer Discov; 2018 Mar; 8(3):336-353. PubMed ID: 29242214
[TBL] [Abstract][Full Text] [Related]
11. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
12. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
Mehlich D; Marusiak AA
Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
[TBL] [Abstract][Full Text] [Related]
13. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
14. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
15. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.
Pfefferle AD; Agrawal YN; Koboldt DC; Kanchi KL; Herschkowitz JI; Mardis ER; Rosen JM; Perou CM
Dis Model Mech; 2016 Jul; 9(7):749-57. PubMed ID: 27149990
[TBL] [Abstract][Full Text] [Related]
17. Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
Lee S; Hu Y; Loo SK; Tan Y; Bhargava R; Lewis MT; Wang XS
Proc Natl Acad Sci U S A; 2020 May; 117(18):9912-9921. PubMed ID: 32321829
[TBL] [Abstract][Full Text] [Related]
18. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic landscape in mutational triple negative breast cancer.
Shi Y; Jin J; Ji W; Guan X
Mol Cancer; 2018 Jul; 17(1):99. PubMed ID: 30007403
[TBL] [Abstract][Full Text] [Related]
20. Metastatic triple-negative breast cancer patient with
Meißner T; Mark A; Williams C; Berdel WE; Wiebe S; Kerkhoff A; Wardelmann E; Gaiser T; Müller-Tidow C; Rosenstiel P; Arnold N; Leyland-Jones B; Franke A; Stanulla M; Forster M
Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
